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OBJECTIVES: Sacral Nerve Modulation (SNM) is a minimally-invasive technology
indicated for overactive bladder (OAB). SNM efficacy has been widely demonstrated
yet its cost-effectiveness in the UK is unknown. The cost-effectiveness of SNM in
patients with refractory idiopathic OAB with urinary incontinence (OAB-wet) was
compared to optimal medical therapy (OMT), Botulinum Toxin A (BoNT-A) and
PTNS from the UK NHS perspective.METHODS:A published Spanish Markov model
was adapted to current UK practice based on existing data and clinical expert
advice. Treatment success was defined as 50% improvement in OAB-wet symp-
toms. Health care resource use included pre-,peri-, and post-procedure; drugs;
follow-ups and adverse events. Both SNM using testing with tined-lead (SNM-
tined-lead) and PNE (SNM-PNE) were evaluated. Incremental-cost-effectiveness-
ratios (ICER;costs per quality-adjusted-life-year)were calculated for SNM vs. OMT
and vs. BoNT-A (10yrs), and SNM vs, PTNS (5yrs); with uni-variate sensitivity
analyses.RESULTS:At 10 years, the cumulative costs of SNM-tined-lead, SNM-PNE,
BoNT-A and OMT were £22,052, £19,952, £18,477, £11,918, respectively; PTNS 5-year
cumulative costs were £17,915.The QALYs for SNM-tined-lead, SNM-PNE, BoNT-A
and OMT were 6.82, 6.64, 6.35 and 5.45 (10yrs), respectively, and 3.44 for PTNS (5yrs).
ICERs were £7,608 and £7,356 for SNM-tined-lead vs. BoNT-A, and vs OMT (10yrs),
respectively; SNM-tined-lead and SNM-PNE were dominant (less costly and more
effective) compared to PTNS (5 years). SNM- tined-lead was cost-effective vs.SNM-
PNE. ICERs were most sensitive to BoNT-A efficacy and costs, but results were
generally robust. CONCLUSIONS: SNM in patients with OAB-wet provides addi-
tional quality of life improvement with higher initial costs for SNM that are offset
by a reduction in follow-up costs over time. This produces ICERs that are clearly
below the threshold generally considered for cost-effectiveness in the UK. SNM
represents value for money compared to OMT, BoNT-A and PTNS, and may be
considered the preferred treatment option in the UK.
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OBJECTIVES: In patients with one to four brain metastasis, if diameter  4 cm, the
standard treatment is whole brain irradiation (WBI) followed by stereotactic radio-
surgery (SRS). There is growing interest on the delivery of isolated SRS, aiming to
reduce side effects of WBI, despite a higher risk of intra-cerebral recurrences. The
objective of this study was to compare the cost-effectiveness of those two strate-
gies, under Brazilians third-part payers’ perspective. METHODS: A meta-analysis
of summary data, including all phase III prospective trails that compared SRS to
WBISRS, was performed. Data about recurrence management, dependant of on
the lesion size, as well as of previous delivered treatment, were also extracted.
Costs were estimated based on charges accordingly to Brazilian Health Care reim-
bursement rates for the private system (CBHPM). Only directs costs were consid-
ered, and were expressed in Brazilian Reais (BRL). A probabilistic sensitivity anal-
ysis was conducted to evaluate the robustness of the results. The perspective was
that from the Brazilian Third Party payer. RESULTS: Three phase III prospective
trials have been selected, including 467 patients. Once there was no difference in
overall survival, effectiveness was evaluated according to local control. After two
years of follow up, 78% [64.2-87.4%] of the SRS patients and 53% [47-57%] of the
WBISRS patients have recurred. The incremental cost-effectiveness ratio (ICER)
comparing WBISRS to SRS was of 7.489,60 BRL/year without cerebral recurrences.
Sensitivity analysis showed that ICER remains acceptable under a wide range of
assumptions . CONCLUSIONS: Results suggested that WBISRS might be consid-
ered as a cost-effective strategy in patients with up to 4 brain metastases. Once no
detrimental survival effect have been shown, SRS can be cost-savings for Brazilians
third-party payers, but patients need to be aware of the risks involved in not deliv-
ering WBI.
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OBJECTIVES: To assess the cost-effectiveness of 3M™ Coban™2 Layer Compres-
sion System (Coban 2) for the treatment of venous leg ulcers in the Dutch health
care setting. METHODS: The health economic evaluation consists of a cost-effec-
tiveness analysis. A Markov model was developed in order to determine the cost-
effectiveness of Coban 2, which was based on different health states and allowed
transitions between these states. Upon initiation of the compression system Coban
2, the patient is supposed to have an ulcer. Over time, the ulcer may heal, but it may
also recur. The treatment with Coban 2 is compared with traditional treatment
(Short Stretch Bandages (SSB)). The primary perspective of the study is that of the
Dutch insurer in 2012. The actual costs, which are included in the study, are prod-
uct costs and treatment costs. Clinical probabilities on healing and recurrence are
derived from clinical published literature. RESULTS: The use of Coban 2 leads to a
total cost of € 600 compared to € 2,663 for traditional care, which leads to cost saving
of € 2,063 per patient over a period of 1 year. The effectiveness for Coban 2 is 84.5%
time without symptoms; the effectiveness for traditional care is 65.0% time with-
out symptoms, which is leading to a gain of 2.3 months without symptoms over
period of 1 year. CONCLUSIONS: The use of Coban 2 versus traditional treatment is
cost-effective, because it is cost saving in combination with a higher effectiveness.
As a consequence the cost savings by Coban 2 also translates into a positive impact
on total health care budget.
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OBJECTIVES: This study evaluated the cost-effectiveness of three leprosy case de-
tection methods in Northern Nigeria to identify the most cost-effective approach to
new case detection for improved leprosy control in Nigeria. METHODS: A cross-
sectional study was carried out to evaluate the additional benefits of using several
case detection methods in addition to routine practice in two north-eastern states
of Nigeria. Primary and secondary data were collected from routine practice re-
cords and the Nigerian Tuberculosis and Leprosy Control Programme of 2009.
Methods evaluated were Rapid Village Survey (RVS), Household Contact Examina-
tion (HCE) and Traditional Healers incentive method (TH). Effectiveness was mea-
sured as number of new leprosy cases detected and cost-effectiveness was ex-
pressed as cost per case detected. Costs were measured from both providers’ and
patients’ perspectives. Additional costs and effects of each method were estimated
by comparing each method against routine practise and expressed as incremental
cost-effectiveness ratio (ICER). All costs were converted to the US Dollar at the 2010
exchange rate. Univariate sensitivity analysis was used to evaluate uncertainties
around the ICER. RESULTS: The ICER for HCE was $142 per additional case detected
at all contact levels and it was the most cost-effective method. At ICER of $194 per
additional case detected, THs method detected more cases at a lower cost than the
RVS which was not cost-effective at $313 per additional case detected. Sensitivity
analysis showed that varying the proportion of shared costs and subsistent wage
for valuing unpaid time did not significantly change the results. CONCLUSIONS:
Complementing routine practice with household contact examination is the most
cost-effective approach to identify new leprosy cases and we recommend that,
depending on acceptability and feasibility, this intervention is introduced for im-
proved case detection in Northern Nigeria.
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OBJECTIVES: To assess the cost-effectiveness of 3M™ CobanTM2 Layer Compres-
sion System (Coban 2) for the treatment of lymphoedema in the Dutch health care
setting. METHODS: The health economic evaluation consists of a cost-effective-
ness analysis. A decision tree model was developed in order to determine the
cost-effectiveness of Coban 2. The entry point of the model consists of patients
with lymphoedema requiring treatment with compression bandages. The treat-
ment with Coban 2 is compared with traditional treatment (Short Stretch Ban-
dages). The primary perspective of the study is that of the Dutch insurer in 2012.
The actual costs, which are included in the study, are product costs and treatment
costs. RESULTS: The use of Coban 2 leads to a mean total cost of € 528 compared to
€ 630 for traditional care, which leads to a cost saving of € 102 per patient. The
effectiveness for Coban 2 is higher because of a shorter treatment period, which
leads to a reduction of the negative impact on Quality of life by lymphoedema.
CONCLUSIONS: The use of Coban 2 versus traditional treatment is cost saving for
each treatment period with a higher effectiveness, due to shorter treatment dura-
tion and improvement in Quality of Life. As a consequence the use of Coban 2 leads
to a positive impact on the total health care budget.
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OBJECTIVES: Functional imaging with positron emission tomography (PET) is a
promising non-invasive modality in the clinical management of squamous cell
carcinoma of the head and neck (SCCHN). Currently, there is limited evidence that
points to the potential cost-effectiveness of PET in this setting. The objective of this
study was to assess the methodological quality of cost-effectiveness analyses
(CEAs) of PET in SCCHN. METHODS: A systematic literature review was performed
focusing on CEAs of PET in SCCHN using MEDLINE, EMBASE, NHS EED and the CEA
Registry. Studies were screened according to a priori eligibility criteria. The meth-
odological quality of the primary clinical studies was examined by QUality Assess-
ment of Diagnostic Accuracy Studies checklist. CEAs were critically appraised us-
ing the Drummond checklist. RESULTS: A total of seven studies met the inclusion
criteria. PET or computed tomography (CT) integrated with PET was assessed in two
indications: detection of recurrent disease and screening for metastasis. In each
indication, PET strategy ranged from likely to be cost-effective (in four studies) to
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